Based on the beneficial effect of FXR and TGR5 agonists in pre-clinical studies on IBD [71,138,139], it would be interesting to investigate whether supplementation of probiotics with high-BSH activity correlates with clinical efficacy in previous studies or warrant their use in future clinical studies. This evidence concerns the gene NR1H4 and irritable bowel syndrome.